Advisory Research’s Kura Oncology KURA Stock Holding History

Advisory Research’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-24,804	Closed	-$357K	–	251
2023 Q4	$357K	Buy	+24,804	New	+$244K	0.06%	276

Other funds holding KURA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Advisory Research's KURA Position: Q1 2024 in Review

Advisory Research sold out of Kura Oncology (KURA) in Q1 2024, closing a stake of 24,804 shares — an estimated $357K sold.

Advisory Research first reported a position in KURA in Q4 2023 and held it in 1 quarter. The position peaked at $357K in Q4 2023. 165 funds tracked by Wall St. Rank hold KURA as of Q1 2024.

Advisory Research reported no remaining Kura Oncology position as of Q1 2024 after selling out during the quarter.
Advisory Research sold 24,804 Kura Oncology shares in Q1 2024, an estimated $357K.
Advisory Research first reported a position in Kura Oncology in Q4 2023 and held it in 1 quarter.
Advisory Research's Kura Oncology position peaked at $357K in Q4 2023.
165 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.